Aiphanol, a native compound, suppresses angiogenesis via dual-targeting VEGFR2 and C0X2  

作　　者：Shanmei Chen Junnan Feng Chuanke Zhao Lixin Wang Lin Meng Caiyun Liu Shaoqing Cai Yanxing Jia Like Qu Chengchao Shou 

机构地区：[1]Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department of Biochemistry and Molecular Biology,Peking University Cancer Hospital&Institute,Beijing,China [2]Key Laboratory of Natural and Biomimetic Drugs,School of Pharmaceutical Sciences,Peking University,Beijing,China [3]Present address:Key Laboratory of Molecular Pathology,The Affiliated Cancer Hospital of Zhengzhou University,Zhengzhou,China

出　　处：《Signal Transduction and Targeted Therapy》2022年第1期22-24,共3页信号转导与靶向治疗（英文）

基　　金：This study was supported by the National Natural Science Foundation of China(81773219);National Basic Research Program of China(2015CB553906);the PKU-Baidu Fund(2019BD015).

摘　　要：Dear Editor,Pathological neo-vascularization is a hallmark of cancer and several diseases.Accumulating evidence supports the notion that antiangiogenic treatment can abolish tumor angiogenesis to achieve Ion ger disease-free survival.Although growth factors and their receptors function as the main drivers in angiogenesis,the involvement of other regulators,e.g.,Cyclooxygenase-2(COX2),^(1) should also be con sidered,especially for managi ng the resista nee to therapies against receptor tyrosine kinases(RTKs).

关 键 词：notion COMPOUND HOUGH 

分 类 号：R730.2[医药卫生—肿瘤]